Hospital versus home treatment of deep vein thrombosis in a tertiary care hospital in Saudi Arabia: Are we ready?

Saudi Pharmaceutical Journal

Volumn 21, Issue 2, 2013, Pages 165-168

  Algahtani, Farjah ^a   Aseri, Zohair Al ^a   AlDiab, Abdurahman ^a   Aleem, Aamer ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Anticoagulation; Deep vein thrombosis; Economic evaluation; Outpatient; Patient safety; Treatment

Indexed keywords

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; ECONOMIC EVALUATION; EMERGENCY WARD; HOME CARE; HOSPITAL CARE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LABORATORY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL FEE; NURSING COST; OUTPATIENT CARE; PATIENT SAFETY; PROSPECTIVE STUDY; SAUDI ARABIA; TERTIARY HEALTH CARE;

EID: 84875804276     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2012.05.008     Document Type: Article

References (23)

1. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch. Intern. Med. 1998, 158:585-593.
2. Nordstrom M., Lundblad B., Bergqvist D., Kjellstrom T. A prosprective study of the incidence of deep-vein thrombosis within a defined urban population. J. Intern. Med. 1992, 232:155-160.
3. Hirsh J. Heparin. N. Engl. J. Med. 1991, 324:1565-1574.
4. Hirsh J., Van Aken W.G., Gallus A.S., Dollery C.T., Cade J.F., Yung W.L. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976, 53:691-695.
5. Hull R.D., Raskob G.E., Brant R.F., Pineo G.F., Valentine K.A. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch. Intern. Med. 1997, 157:2562-2568.
6. Simonneau G., Charbonnier B., Decousus H., et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch. Intern. Med. 1993, 153:1541-1546.
7. Hull R.D., Raskob G.E., Pineo G.F., et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 1992, 326:975-982.
8. Lindmarker P., Holmstrom Comparison of once-daily Subcutinuos Fragmin with continuous intravenous UFH in the treatment of deep vein thrombosis. Thromb. Haemost. 1994, 72:186-190.
9. Fiessinger J.N., Lopez Once daily with sucutinuous daltaparin LMWH for intitial treatment of acute deep vein thrombosis. Thromb. Haemost. 1996, 76:1195-1199.
10. The Columbus Investigators, LMWH in the treatment of patients with venous thrombosis, 1997. N. Engl. J. Med. 337, 657-662.
11. Merli G., Spiro T.E., Olsson C.G., et al. For the Enoxaparin clinical trial group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann. Intern. Med. 2001, 134:191-202.
12. Leizorovicz A., Simonneau G., Decousus H., Boissel J.P. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br. Med. J. 1994, 309:299-304.
13. Lensing A.W., Prins M.H., Davidson B.L., Hirsh H. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch. Intern. Med. 1995, 155:601-607.
14. Siragusa S., Cosmi B., Piovella F., Hirsh J., Ginsberg J.S. Low-molecular-weight unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. 1996, 100:269-277.
15. Walenga J.M., Hoppensteadt D., Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparin. Thromb. Res. 1991, 14(Suppl):49-62.
16. Prandoni P., Lensing A.W., Buller H.R., et al. Comparison of subcutaneous low-molecular-weight heparin with intra-venous standard heparin in proximal deep-vein thrombosis. Lancet 1992, 339:441-445.
17. Van den Belt A.G., Bossuyt P.M., Prins MHm Vallus A.S., Buller H.R. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. TASMAN study group. Thromb. Haemost. 1998, 79:259-263.
18. Gould M.K., Dembitzer A.D., Sanders G.D., Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann. Intern. Med. 1999, 130:789-799.
19. Belcaro G., Nicolaides A.N., Cesarone M.R., et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered at home for deep-vein thrombosis. Angiology 1999, 50:781-787.
20. Lindmarker P., Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Thrombosis Dalteparin trial group. J. Intern. Med. 1996, 240:395-401.
21. Goldhaber S.Z., Tapson V.F. DVT FREE Steering Committee. A prospective registry of 5,451patients with ultrasound-confirmed deep vein thrombosis. Am. J. Cardiol. 2004, 93:259-262.
22. Spyropoulos A.C. Outpatient protocols for treatment of venous thromboembolism using low molecular weight heparin: to treat or not to treat at home. Arch. Intern. Med. 1999, 159:1139-1140.
23. Tillman D.J., Charland Sl, Witt D.W. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch. Intern. Med. 2000, 1460:2926-2932.